Key Findings
- Evaluation of 8,263 HR-positive breast cancers profiled by Caris showed that tumors with BRCA1/2 or PALB2 pathogenic variants had shorter time on endocrine therapy and CDK4/6 inhibitors, but longer time on PARP inhibitor therapy, compared with wildtype disease.
- This study demonstrates how integrated genomic, transcriptomic, and immune profiling can identify biologically distinct breast cancer subgroups, refine therapeutic stratification, and uncover potential biomarkers of treatment response and resistance across metastatic, hormone receptor–positive, and triple-negative disease.